Nxera Pharma Co., Ltd.
4565.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | ¥94,032,848 | ¥117,256,657 | ¥174,856,347 | ¥154,580,048 |
| - Cash | ¥32,268,000 | ¥49,065,000 | ¥66,557,000 | ¥60,087,000 |
| + Debt | ¥67,900,000 | ¥73,973,000 | ¥29,734,000 | ¥29,271,000 |
| Enterprise Value | ¥129,664,848 | ¥142,164,657 | ¥138,033,347 | ¥123,764,048 |
| Revenue | ¥28,835,000 | ¥12,766,000 | ¥15,569,000 | ¥17,712,000 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Gross Profit | ¥21,219,000 | ¥9,664,000 | ¥14,643,000 | ¥16,779,000 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| EBITDA | ¥105,000 | -¥5,707,000 | ¥3,567,000 | ¥2,189,000 |
| % Margin | 0.4% | -44.7% | 22.9% | 12.4% |
| Net Income | -¥4,838,000 | -¥7,193,000 | ¥382,000 | ¥1,017,000 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS Diluted | -53.92 | -87.17 | 4.63 | 12.4 |
| % Growth | 38.1% | -1,982.7% | -62.7% | – |
| Operating Cash Flow | -¥7,718,000 | -¥5,273,000 | ¥9,952,000 | ¥7,095,000 |
| Capital Expenditures | -¥526,000 | -¥851,000 | -¥303,000 | -¥201,000 |
| Free Cash Flow | -¥8,244,000 | -¥6,124,000 | ¥9,649,000 | ¥6,894,000 |